55687-33-7

Basic information

• Product Name: 2-CHLORO-6-FLUOROQUINOXALINE
• Synonyms: 2-CHLORO-6-FLUOROQUINOXALINE;Quinoxaline,2-chloro-6-fluoro-
• CAS NO: 55687-33-7
• Molecular Formula: C₈H₄ClFN₂
• Molecular Weight: 182.58
• Mol File: 55687-33-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 129-132 °C
• Boiling Point: 257.1 °C at 760 mmHg
• Flash Point: 109.3 °C
• Appearance: /
• Density: 1.447g/cm³
• Vapor Pressure: 0.0239mmHg at 25°C
• Refractive Index: 1.634
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.02±0.30(Predicted)
• CAS DataBase Reference: 2-CHLORO-6-FLUOROQUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-FLUOROQUINOXALINE(55687-33-7)
• EPA Substance Registry System: 2-CHLORO-6-FLUOROQUINOXALINE(55687-33-7)

Safety Data

• Hazardous Substances Data: 55687-33-7(Hazardous Substances Data)

Usage

Description

2-Chloro-6-fluoroquinoxaline is an organic compound that belongs to the quinoxaline family. It is characterized by the presence of a chlorine atom at the 2nd position and a fluorine atom at the 6th position in the quinoxaline ring. 2-CHLORO-6-FLUOROQUINOXALINE is known for its potential applications in the synthesis of various quinoxaline derivatives, which have diverse biological activities and uses.

Uses

Used in Pharmaceutical Industry:
2-Chloro-6-fluoroquinoxaline is used as a key intermediate in the synthesis of quinoxaline-based compounds, which have potential applications as antidotes for acetanilide herbicides. These antidotes can help counteract the toxic effects of these herbicides, providing a valuable solution for agricultural and environmental purposes.
Additionally, quinoxaline derivatives have been found to possess a range of biological activities, including antimicrobial, antiviral, and anticancer properties. As a result, 2-chloro-6-fluoroquinoxaline can be utilized in the development of new drugs and therapeutic agents for various medical applications.

InChI:InChI=1/C8H4ClFN2/c9-8-4-11-7-3-5(10)1-2-6(7)12-8/h1-4H

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 367-31-7 4-fluoro-1,2-phenylenediamine 
• 145323-53-1 7-fluoro-1,2-dihydroquinoxalin-2-one 
• 55687-23-5 6-fluoroquinoxalin-2(1H)-one 
• 148010-65-5 6-fluoro-1,2,3,4-tetrahydroquinoxalin-2-one 
• 55687-24-6 N-(5-fluoro-2-nitrophenyl)glycine ethyl ester 
• 446-35-5 2,4-Difluoronitrobenzene 

Downstream Products

• 21335-55-7 n-pentenyl alcohol 
• 1621366-64-0 N-(3,4-difluorophenyl)-5-[(6-fluoroquinoxalin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide 
• 1621366-38-8 N-(2-ethylphenyl)-5-[(6-fluoroquinoxalin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide 
• 76578-80-8 6-fluoro-2-(4-hydroxyphenoxy)-quinoxaline 
• 112080-06-5 2,6-Difluoro-quinoxaline 

Relevant articles and documents

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.

A FACILE SYNTHESIS OF NOVEL TRICYCLIC COMPOUNDS, TETRAZOLOQUINOXALINES AND 1,2,4-TRIAZOLOQUINOXALINES

Novel 5-methyltetrazoloquinoxalin-4-ones (5) and 5-methyl-1,2,4-triazoloquinoxalin-4-ones (7) could be synthesized from 1-methyl-3-chloroquinoxalin-2-ones (3) and 1-methyl-3-hydrazinoquinoxalin-2-ones (6), respectively.Further extensive study was carried out to synthesize 4- or 7- substituted and 4,7-disubstituted tetrazoloquinoxalines (10) and 1,2,4-triazoloquinoxalines (12).